KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 156 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 4.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,873 | -56.1% | 1,397,543 | -41.3% | 0.02% | -48.6% |
| Q2 2023 | $4,265 | +13.4% | 2,382,451 | +115.4% | 0.04% | -36.4% |
| Q4 2022 | $3,761 | -99.9% | 1,106,132 | +56.4% | 0.06% | +7.8% |
| Q3 2022 | $3,862,000 | +32.6% | 707,280 | +9.5% | 0.05% | +41.7% |
| Q2 2022 | $2,913,000 | +1922.9% | 645,985 | +3215.0% | 0.04% | +1700.0% |
| Q1 2022 | $144,000 | -79.4% | 19,487 | -82.1% | 0.00% | -71.4% |
| Q4 2021 | $700,000 | +302.3% | 108,896 | +264.0% | 0.01% | +250.0% |
| Q3 2021 | $174,000 | -37.9% | 29,920 | +10.3% | 0.00% | -33.3% |
| Q2 2021 | $280,000 | +2.6% | 27,120 | +4.7% | 0.00% | -25.0% |
| Q1 2021 | $273,000 | -17.5% | 25,911 | +14.2% | 0.00% | -42.9% |
| Q3 2020 | $331,000 | -40.0% | 22,695 | -21.1% | 0.01% | -76.7% |
| Q1 2020 | $552,000 | -42.0% | 28,751 | -71.0% | 0.03% | -9.1% |
| Q3 2019 | $952,000 | +514.2% | 98,993 | +283.7% | 0.03% | +450.0% |
| Q2 2019 | $155,000 | – | 25,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Delphi Management Partners VIII, L.L.C. | 2,263,006 | $13,170,000 | 9.51% |
| Palo Alto Investors LP | 5,383,052 | $31,329,000 | 1.89% |
| Birchview Capital, LP | 246,000 | $1,432,000 | 0.97% |
| Rubric Capital Management LP | 3,375,758 | $19,647,000 | 0.55% |
| Lombard Odier Asset Management (Switzerland) SA | 1,517,804 | $8,834,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,401,861 | $8,159,000 | 0.30% |
| AlphaCentric Advisors LLC | 136,000 | $792,000 | 0.20% |
| Bridgefront Capital, LLC | 20,946 | $122,000 | 0.13% |
| Hennion & Walsh Asset Management, Inc. | 407,474 | $2,371,000 | 0.12% |
| Virtus ETF Advisers LLC | 44,364 | $258,000 | 0.11% |